Estimating the effectiveness of chemotherapy in breast cancer
Half of breast cancers are in women over the age of 65, but the average age in trials is closer to 50 and only very fit and healthy women are typically eligible for trials.
It is unknown if chemotherapy benefits seen in clinical trials are the same in typical NHS real-world patients.
Reliable methods for estimating the benefits and harms of chemotherapy in NHS patients are urgently required to help patients make difficult decisions about whether or not to undergo chemotherapy.
The SATURNE project aimed to find out if new methods from econometrics and data science could help us address this need.